We are looking forward to further clarification from the FDA regarding the risks associated with testosterone treatments.
New York, New York (PRWEB) September 13, 2014
As testosterone lawsuit (http://www.drugbot.com/testosterone/lawsuit/) filings continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) will convene a meeting of outside advisors on Wednesday, September 17th, to investigate the cardiovascular risks associated with low testosterone therapies. The meeting is part of the FDA review of prescription medications used to treat hypogonadism (low testosterone levels) in men that was announced by the agency in January, after studies suggested that the medications may increase the risk of heart attacks, strokes and death in certain men.*
“Our Firm has heard from numerous men who allegedly suffered life-threatening cardiovascular side effects due to their use of low testosterone therapy. We are looking forward to further clarification from the FDA regarding the risks associated with these medications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.
According to the FDA, Wednesday’s meeting will involve two of the agency’s advisory panels, the Bone, Reproductive and Urologic Drug Advisory Committee, and the Drug Safety and Risk Management Committee. Panel members will discuss the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use.*
According to a briefing document issued by the FDA in advance of the advisory panel meeting, 2.3 million U.S. patients received a prescription for testosterone last year, an increase of 77 percent from 2010. However, agency reviewers concluded that there was little evidence to indicate that low testosterone therapy provided any benefits for men who used the drugs to alleviate fatigue, low libido and other symptoms associated with aging.
Court documents indicate that more than 170 testosterone treatment lawsuits have been filed in the Northern District of Illinois on behalf of men who used AndroGel, Testim, AndroDerm and similar drugs since the FDA announced its review in January. Among other things, these claims accuse the defendants of failing to warn doctors and patients about their potential to cause life-threatening cardiovascular events, and of concealing those risks from the public. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Men who used a testosterone replacement medication may be entitled to compensation if they experienced heart attacks, strokes, blood clots, or other cardiovascular events allegedly associated with the drugs. To learn more, please visit Bernstein Liebhard LLP’s website, or call the Firm today at 800-511-5092.
*http://www.fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm, FDA, July 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com